A fluorescence polarization immunoassay evaluated for quantifying astromicin, a new aminoglycoside antibiotic.
We evaluated a fluorescence polarization immunoassay (FPIA) procedure for measuring astromicin, a new aminoglycoside antibiotic. The calibration curve can be stored for at least 32 days without loss of accuracy. There were no interferences from hemoglobin (up to 4000 mg/L) or bilirubin (up to 200 mg/L), nor were there any cross-reactivities with amikacin, gentamicin, or tobramycin. Within-run precision (CV) for 20 replicates, each at concentrations of 5, 15, and 25 mg/L, was 1.25-2.11%. Between-run precision for these same concentrations, measured on five occasions, was 2.13-2.74%. Linear-regression analyses of data by FPIA (y) and HPLC (x) for plasma obtained from six healthy male volunteers who were given 200 mg of astromicin by 30-min intravenous infusion and for sera prepared by adding arbitrary amounts of astromicin showed highly significant correlations: r = 0.996 (n = 66), y = 0.96x - 0.48 mg/L and r = 0.981 (n = 59), y = 0.96x - 0.25 mg/L, respectively. This assay offers a rapid, efficient, and accurate system for therapeutic monitoring of astromicin in blood.